Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-apoptosis-inducing lingand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential

Journal of Orthopaedic Research

Volumn 21, Issue 5, 2003, Pages 949-957

  Hotta, Takahito ^a,b   Suzuki, Hidekazu ^a,b   Nagai, Shuzou ^b   Yamamoto, Kengo ^b   Imakiire, Atsuhiro ^b   Takada, Eiko ^a   Itoh, Mizue ^a   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Chemotherapy; Osteosarcoma; Sensitization; TRAIL

Indexed keywords

BIOLOGICAL MEMBRANES; CELLS; TUMORS;

SARCOMA CELL LINES;

ORTHOPEDICS;

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CELL RECEPTOR; CISPLATIN; DOXORUBICIN; LIPOCORTIN 5; PROPIDIUM IODIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; WESTERN BLOTTING;

EID: 0041386055     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-0266(03)00062-7     Document Type: Article

References (46)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
2. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
3. Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, et al. Sensitization of resistant lymphoma, cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 2001;20:2190-6.
4. Bramwell VH. Osteosarcomas and other cancers of bone. Curr Opin Oncol 2000;12:330-6.
5. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
6. Ceraline J, Deplanque G, Duclos B, Limacher JM, Hajri A, Noel F, et al. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer 1998;75:432-8.
7. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott-Raven; 1996. p. 297-332.
8. Chandar N, Billig B, McMaster J, Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 1992; 65:208-14.
9. Colvin OM. Drug resistance in the treatment of sarcomas. Semin Oncol 1997;24:580-91.
10. Decaudin D, Marzo II, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (Review). Int J Oncol 1998;12:141-52.
11. Eilber FR, Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin Oncol 1989;16:312-22.
12. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99:491-504.
13. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10:559-63.
14. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nature Rev Cancer 2001;1:142-50.
15. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
16. Itoh M, Noutomi T, Toyota H, Mizuguchi J. Etoposide-mediated sensitization of squamous cell carcinoma cells of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Oral Oncol 2003;39:269-76.
17. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734-41.
18. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002;277:22320-9.
19. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-20.
20. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645-51.
21. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501.
22. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
23. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
24. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545-56.
25. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999;190:1033-8.
26. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002;39:167-76.
27. Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 2001;493:65-9.
28. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-53.
29. L confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol 2002;38:41-8.
30. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
31. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999;11:68-75.
32. Reed JC, Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death Differ 2000;7:1145.
33. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
34. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274:1541-8.
35. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254:439-59.
36. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998;58:1593-8.
37. L can differentially block chemotherapy-induced cell death. Blood 1997; 90:1208-16.
38. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
39. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001;3:535-46.
40. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998;1366:151-65.
41. Takada E, Toyota H, Suzuki J, Mizuguchi J. Prevention of anti-IgM-induced apoptosis accompanying G1 arrest in B lymphoma cells overexpressing dominant-negative mutant form of c-Jun N-terminal kinase 1. J Immunol 2001;166:1641-9.
42. Trieb K, Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 2001;33:11-7.
43. L-overexpressing chemotherapy-resistant tumor cells. Cancer Res 2000;60:3051-7.
44. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
45. Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17(III):141-3.
46. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999;59:2747-53.